Replies to post #263534 on Anavex Life Sciences Corp (AVXL)

[Steady_T]

I think it is more likely that Missling learned a lesson with the bogus class action suit filed against the company. That cost the company time and scarce resources and also made it clear that the shorts would use any dirty trick or opportunity to damage the share price.

Since then Missling has walked the very straight and narrow so to not provide another opportunity for those sorts of shenanigans.

He probably could provide more information than he does without much risk. But given the potential harm and the large short position, playing it very safe is a good plan. After all, it is the trial results that will decide the fate of the company, not well received conference calls.

[Jonjones325]

https://arts.unimelb.edu.au/__data/assets/pdf_file/0012/3183789/John-Skerritt.pdf

Ok. Ran into this while doing some DD. Trying to find more info on this. Having a difficult time but may shed light on why Missling didn’t say what he wanted to say. This was what I found so far but am having a hard time finding a more definitive/relevant source. Super sleuths?? Found this on one of the slides. Just a dot. I think.

Cannot advertise an unapproved medicine to doctors or the public
?Cannot advertise SAS products at all
?A clinical trial sponsor is able to promote the trial publicly but cannot specifically mention the name of the medicine being used in the trial

[frrol]

Missling is either a (A) wily or (B) sneaky.

Or... (C), he's a biotech manager who told the truth.

The simple answer, as shocking and mind blowing as it may seem, is C. He conveyed what he was told by the TGA. Three times. It may not be what you wanted to hear, but you can't blame him for that. And it was good news.